<DOC>
	<DOCNO>NCT01371227</DOCNO>
	<brief_summary>The purpose study evaluate tolerability combination therapy JNS002 bortezomib Japanese bortezomib-naive patient multiple myeloma ever receive least 1 line chemotherapy .</brief_summary>
	<brief_title>A Study JNS002 ( Doxorubicin Hydrochloride Liposome Injection ) Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>This non-randomized ( study drug intentionally assign patient ) , single-arm ( one group patient receive treatment ) , open-label ( people involve know identity intervention ) study evaluate tolerability combination therapy JNS002 bortezomib 3 6 patient multiple myeloma whose disease either progress least 1 line prior therapy refractory initial treatment . Initially , 3 patient enrol incidence dose limit toxicity ( DLT ) determine end Cycle 1 evaluate study dose maximum tolerate dose ( MTD ) . If incidence =2/3 , additional 3 patient enrolled define MTD . Safety endpoint include adverse event , laboratory test ( hematology , blood biochemistry , urinalysis ) , electrocardiogram ( ECG ) , LVEF , chest X-ray , vital sign ( body temperature , pulse rate , blood pressure ) , body weight . Efficacy evaluation perform term antitumor effect , accord criterion assessment antitumor effect similar European Group Blood Marrow Transplantation ( EBMT ) criterion . Bortezomib 1.3 mg/m2 rapid ( bolus ) intravenous ( IV ) administration give Days 1 , 4 , 8 , 11 21-day cycle . In addition , JNS002 30 mg/m2 IV infusion give rate = 1 mg/minute Day 4 every 21-day cycle bortezomib . Treatment continue total 6 cycle therapy ( 126 day ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients confirm diagnosis multiple myeloma evaluable disease parameter ( 1.Presence Mprotein serum and/or urine , 2.Increased plasma cell bone marrow biopsyproven plasmacytoma , 3.Presence related organ tissue impairment ) Patients progression disease initial response ( complete , partial , minimal response base EBMT criterion ) least 1 line therapy . Progression disease respond initial line therapy nonanthracycline contain regimen include ( minimum ) alkylating agent highdose corticosteroid . Rituximab alone experimental agent alone consider line therapy Patients progressive disease define one following : ) &gt; 25 % increase Mprotein , ii ) Development new worsen lytic bone lesion , iii ) Development new worsen plasmacytoma , iv ) Development new worsen hypercalcemia ( &gt; 11.5 mg/dL 2.8 mmol/L correct ) attributable cause Patients measurable secretory disease define either : ) Serum monoclonal protein &gt; 1 g/dL , ii ) Urine monoclonal ( light chain ) protein &gt; 200 mg/24 hour Patients Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 . ECOG performance status score 2 due pain associate bone disorder eligible . Patients history treatment bortezomib Patients progressive disease receive anthracyclinecontaining regimen Patients change ( NC ) disease status initial therapy ( patient must response progression progression receive initial therapy [ primary refractory disease ] Patients nonsecretory disease ( i.e. , measurable paraprotein serum urine urine paraprotein level = 200 mg/24 hour ) Patients prior treatment doxorubicin anthracycline cumulative dos great 240 mg/m2 ( calculate use doxorubicin equivalent dos : 1 mg doxorubicin = 1 mg JNS002 = 1.8 mg epirubicin = 0.3 mg mitoxantrone = 0.25 mg idarubicin ) Patients Grade 1 peripheral neuropathy pain Grade 2 high peripheral neuropathy , accord Common Terminology Criteria Adverse Events ( CTCAE ) Patients clinically significant heart disease , New York Heart Association ( NYHA ) Class II high heart failure Patients viral hepatitis chronic liver disease Patients pulmonary fibrosis interstitial pneumonitis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Relapsed refractory multiple myeloma</keyword>
	<keyword>JNS002</keyword>
	<keyword>Bortezomib</keyword>
</DOC>